AnchorWatch Trust Company introduced a Bitcoin custody service on October 19, offering clients insurance coverage up to $370 million each. This coverage is underwritten by Lloyd's of London and available to U.S. residents and companies. Clients can choose between two custody models involving key control shared with AnchorWatch, BitGo, and CoinCorner. Custody fees are capped at $10,000 monthly regardless of Bitcoin holdings or gains, with insurance priced separately based on risk profiles.
AnchorWatch's new Bitcoin custody service with $370 million insurance coverage provides a backdrop for cryptocurrency market activity. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 20, 2026 04:42 WIB: out of 50 major cryptocurrencies priced on Pluang, 46 rose and 3 fell. Notable movers include SXP (Solar) down 46.27% at Rp37 with a typical hold time of 94 days, BAT (Basic Attention Token) up 15.27% at Rp3,544 with a typical hold time of 93 days and a near-even Pluang order activity split, and CRV (Curve DAO Token) up 11.35% at Rp6,603 with a typical hold time of 62 days but 99% sell order activity.
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Nvidia announced a nearly $10 billion investment plan to support Europe's AI ecosystem, focusing on four German startups: Agile Robots, Avelios Medical, Mirelo, and Reflex Aerospace. This move aligns with Germany's goal to lead in industrial AI, with...
Recce Pharmaceuticals has reached a key milestone in its Phase 3 trial for treating diabetic foot infections with its RECCE® 327 Gel (R327G). An independent Data Monitoring Committee will review unblinded data from 75 patients, following encouraging ...
